INDIA MARKET LENS
Companies◆ Mixed

Dr Reddy's receives DCGI approval for esophageal cancer drug Zytorvi

Dr Reddy set out an expansion.

· BS Companies

Dr Reddy's Laboratories on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for Zytorvi (toripalimab), through which it aims to expand access to first-line immunotherapy for patients with advanced esophageal squamous cell carcinoma (ESCC) in India.

Continue in the original report ↗

Dr Reddy reported movement of 80%. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.

Against that, the stock is +0.5% on the day at ₹1,352.00, and has returned +18.1% over three months. It is trading close to its 52-week high, so expectations were already elevated going in. The pharma & healthcare sector has moved -0.9% over the same period, so Dr Reddy is running 19.0 points ahead of its peers.

For Dr Reddy, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.

  • In focus: Dr Reddy (DRREDDY), in Pharma & Healthcare.
  • Over three months: Dr Reddy +18.1% against Pharma & Healthcare -0.9% (19.0 points ahead).
Figures for the companies in this story
CompanyPriceDay1M3MFrom 52-wk highVolume vs 20-dayMarket cap
Dr ReddyDRREDDY · Pharma & Healthcare₹1,352.00+0.5%+9.7%+18.1%-1.7%0.8×—

Pharma & Healthcare

1M -0.6% · 3M -0.9%

Dr Reddy

Prices as of 30 Oct 2026, 16:10 IST. Sector moves are the average of the stocks we track in each sector.

DRREDDYPharma & Healthcare